Recent Updates
Recently added Catalysts

PhosphoLean

Phase 1

Weight Loss | Small molecule | Other |The Cooper Companies, Inc.|Last Updated: Mar 12, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment60
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00153790LEAN Project: Weight Loss and Appetite SuppressionPHASE1 COMPLETED 60Apr 1, 2005May 1, 2006Mar 12, 2014 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
PhosphoLeanDRUG -
Unlock Study Design Details